Figure 2: Circulating concentration of (A) ALT (IU/L), (B) miR-122 (fM) and (C) K18 (U/L) in sequential samples in patients within the ALISTER study, (active TB n=9; latent TB n=46; NTM n=10) Data shown as dot plots. Black dots show patients with normal ALT activity at baseline and on treatment; blue dots show patients with ALT activity >50U/L at baseline which decreased on treatment; red dots show patients whose ALT increased above 50U/L with treatment. Dotted line on (A) ALT = 50 IU/L. The significance of differences between baseline and on treatment concentrations of biomarkers was determined by Wilcoxon signed rank test (ALT P=0.03; miR-122 P=0.01; K18 P=0.4).